Xtant Medical

2016 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014

Xtant Medical Receives FDA Clearance for the Xsert™ Lumbar Expandable Interbody System

11/23/16

BELGRADE, Mont., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has...

Read More

Xtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million

11/17/16

BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of ...

Read More

Xtant Medical Receives FDA Clearance to Use Allografts in the Stand-Alone Irix-C™ Cervical Cage

11/15/16

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has...

Read More

Xtant Medical Announces Expiration of Rights Offering and Estimated Gross Proceeds of $3.8 Million

11/15/16

BELGRADE, Mont., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that the subscr...

Read More

Xtant Medical Announces First Surgical Cases of Xspan™ Laminoplasty Fixation System

11/14/16

BELGRADE, Mont., Nov. 14, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the first surgical cases of the Xspan Laminoplasty F...

Read More

Xtant Medical Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period and Final Subscription Price

11/11/16

BELGRADE, Mont., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, reminds rights holders that the...

Read More

Xtant Medical Announces Adjustment to Subscription Price of Rights Offering

11/09/16

BELGRADE, Mont., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has adj...

Read More

Xtant™ Medical Holdings Reports Record Third Quarter 2016 Results

11/07/16

*See footnote about the use of pro forma financial information Third Quarter 2016 Highlights: Company revenue increased 10.5% to $23.1 million, as compared to pro forma revenue of $20.9 million in third quarter 2015 Gross profit increased ...

Read More

Xtant Medical Receives Approval of Compliance Plan from NYSE MKT

11/01/16

BELGRADE, Mont., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE M...

Read More

Xtant Medical Announces Commencement of Subscription Period for Previously Announced Rights Offering

10/31/16

BELGRADE, Mont., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today that it has com...

Read More

Xtant Medical Reminds Shareholders That Rights Offering Ownership Day is Tuesday, October 18, 2016 at 4:00 PM ET

10/18/16

BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, provides stockholders and conve...

Read More

Xtant Medical Holdings, Inc. to Report Third Quarter 2016 Financial Results on November 7, 2016

10/18/16

BELGRADE, Mont., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the p...

Read More

Xtant™ Medical Pre-Announces Record Third Quarter 2016 Revenue

10/11/16

*See footnote about the use of pro forma financial information Record Third Quarter 2016 Revenue in the range of $23.0 million to $23.3 million Third Quarter 2016 Revenue represents an increase of 10.0% to 11.5% compared to pro forma Thir...

Read More

Xtant Medical Announces the Appointment of Carl O’Connell as President

10/06/16

BELGRADE, Mont., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Carl O’Connell as President, repo...

Read More

Xtant Medical Announces Key Dates Related to Previously Announced Rights Offering

10/06/16

BELGRADE, Mont., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today provided an informational...

Read More

Xtant Medical Files S-1 Registration Statement for Rights Offering to Shareholders

08/29/16

BELGRADE, Mont., Aug. 29, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced it filed a regi...

Read More

Xtant Medical Receives Non Compliance Notice from NYSE MKT

08/19/16

BELGRADE, Mont., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that the NYSE M...

Read More

Xtant Medical Expands AR Credit Facility with Silicon Valley Bank

08/16/16

Expanded credit facility to provide additional liquidity for future growth BELGRADE, Mont., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic prod...

Read More

Xtant™ Medical Reports Second Quarter 2016 Results

08/01/16

*See footnote about the use of pro forma financial information Second Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 5.6% to $20.9 million compared to core pro forma recurring revenue of $19.8 mill...

Read More

Xtant™ Medical Announces the Operations Expansion of Montana’s Tissue Processing Rooms

07/26/16

BELGRADE, Mont., July 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the expansion of its tissue processing facility in B...

Read More

Xtant™ Medical Pre-Announces Second Quarter 2016 Revenue and EBITDA

07/20/16

Second Quarter 2016 Revenue in the range of $21.45 million to $21.65 million Core recurring revenue to increase 5.6% to 6.6% over the same period last year EBITDA projected to be $300,000-$400,000 for Second Quarter 2016 BELGRADE, Mont., Jul...

Read More

Xtant Medical Holdings, Inc. to Report Second Quarter 2016 Financial Results on August 1, 2016

07/19/16

BELGRADE, Mont., July 19, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the perio...

Read More

Xtant™ Medical Announces Changes to Its Executive Management and Board of Directors

06/16/16

BELGRADE, Mont., June 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Paul Buckman, Eric Timko, and Rud...

Read More

Xtant Medical and Pinnacle Spine Group Announce Distribution Agreement, Expanding the Availability of Innovative InFill® Lateral Fusion System

06/08/16

BELGRADE, Mont. and DALLAS, June 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices and Pinnacle Spine Group, LLC, a developer of innovative s...

Read More

Xtant Medical Completes New Accounts Receivable Revolver Credit Facility with Silicon Valley Bank

05/26/16

New facility provides additional working capital to continue Company market expansion plans BELGRADE, Mont., May 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketin...

Read More

Xtant Medical to Present at Investor Conferences

05/17/16

BELGRADE, Mont., May 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development, manufacturing and marketing of orthopedic products for domestic and interna...

Read More

Xtant Medical Sets Annual Meeting and Record Dates

05/13/16

BELGRADE, Mont., May 13, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, has established a record date fo...

Read More

Xtant™ Medical Announces the FDA Clearance for the Posterior Cervical Screw Indication on Certex® Spinal Fixation System

05/12/16

BELGRADE, Mont., May 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced FDA clearance for the posterior cervical screw indica...

Read More

Xtant™ Medical Reports First Quarter 2016 Results

05/04/16

See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to core pro forma recurring revenue of $19.2 million ...

Read More

Xtant Medical Holdings, Inc. to Report First Quarter 2016 Financial Results on May 4, 2016

04/27/16

BELGRADE, Mont., April 27, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the ...

Read More

Xtant Medical Announces Montana Department of Commerce Grant Awards

04/26/16

BELGRADE, Mont., April 26, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the awarding of two grants from the Montana Departm...

Read More

Xtant Medical Pre-Announces First Quarter 2016 Revenue

04/19/16

Core recurring revenue to increase 7% to 8% over first quarter 2015 The Company reiterates full-year 2016 revenue guidance of $94 million to $99 million and EBITDA guidance of $4.3 million to $6.3 million BELGRADE, Mont., April 19, 2016 ...

Read More

Xtant Medical Announces FDA Clearance of the Xspan™ Laminoplasty Fixation System

03/30/16

BELGRADE, Mont., March 30, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that its wholly owned subsidiary, X-spine Systems, ...

Read More

Xtant Medical Announces Distribution Agreement with Vivex Biomedical Bringing OsteoVive™, a Cellular Allograft, to Market

03/24/16

BELGRADE, Mont., March 24, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a leader in the development of regenerative medicine products and medical devices, is expanding its biologics portfolio through a distribution relationshi...

Read More

Xtant™ Medical Reports Record $22.3 Million Revenue and 14.1% Growth for the Fourth Quarter 2015

03/15/16

See footnote about the use of pro forma financial information Fourth Quarter 2015 Highlights: Consolidated total revenue increased 14.1% to a record $22.3 million compared to pro forma fourth quarter 2014 revenue of $19.5 million Consolida...

Read More

Xtant Medical Holdings, Inc. to Report Fourth Quarter 2015 Financial Results on March 15, 2016

03/08/16

BELGRADE, Mont., March 08, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the ...

Read More

Xtant™ Medical Receives CE Mark for Its Aranax™ Cervical Plating System and Irix-A™ Stand Alone Anterior Lumbar Interbody Fusion Device

03/03/16

BELGRADE, Mont., March 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced CE clearance for its products Aranax™ and Irix-A™. ...

Read More

Xtant™ Medical to Present at the Canaccord Genuity 2016 Musculoskeletal Conference

02/16/16

BELGRADE, Mont., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today ...

Read More

PR: Xtant™ Medical to Present at the Source Capital 2016 Disruptive Growth & Healthcare Conference

02/03/16

BELGRADE, Mont., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today ...

Read More

Xtant Medical Holdings, Inc. Reports Preliminary Fourth Quarter 2015 Financial Results

01/12/16

BELGRADE, Mont., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced preliminary results of its fourth quarter 2015 and p...

Read More